

Supplemental Material

Table S1. Patient characteristics overall and by race/ethnicity.

<i>Variable</i>	<i>All patients</i> n=21528 (%)	<i>Non-Hispanic White</i> n=8202 (%)	<i>Hispanic</i> n=5478 (%)	<i>Non-Hispanic Black</i> n=5531 (%)	<i>Native American</i> n=106 (%)	<i>Asian</i> n=857 (%)	<i>Pacific Islander</i> n=78 (%)	<i>Other</i> n=1276 (%)	<i>p-value</i>
Sex									
Male	11644 (54.1)	4482 (54.6)	3117 (56.9)	2733 (49.4)	52 (49.1)	478 (55.8)	34 (43.6)	748 (58.6)	<.001
Female	9884 (45.9)	3720 (45.4)	2361 (43.1)	2798 (50.6)	54 (50.9)	379 (44.2)	44 (56.4)	528 (41.4)	<.001
Age, year (SD)	61.2 (17.9)	67.0 (17.3)	55.2 (17.6)	59.0 (16.6)	58.7 (17.4)	62.4 (17.1)	48.4 (16.9)	60.2 (17.9)	<.001
Deep vein thrombosis	725 (3.4)	368 (4.5)	91 (1.7)	217 (3.9)	1 (0.9)	10 (1.2)	0	38 (3.0)	<.001
Pulmonary embolism	487 (2.3)	241 (2.9)	40 (0.7)	172 (3.1)	2 (1.9)	8 (0.9)	0	24 (1.9)	<.001
Cerebrovascular disease	2608 (12.1)	1054 (12.9)	551 (10.1)	809 (14.6)	13 (12.3)	77 (9.0)	5 (6.4)	99 (7.8)	<.001
Stroke	2060 (9.6)	796 (9.7)	436 (8.0)	667 (12.1)	11 (10.4)	64 (7.5)	5 (6.4)	81 (6.3)	<.001
Transient ischemic attack	625 (2.9)	327 (4.0)	90 (1.6)	178 (3.2)	2 (1.9)	13 (1.5)	0	15 (1.2)	<.001
Coronary artery disease									
Prior CABG	627 (2.9)	401 (4.9)	72 (1.3)	98 (1.8)	2 (1.9)	17 (2.0)	3 (3.8)	34 (2.7)	<.001
Prior PCI	986 (4.6)	568 (6.9)	138 (2.5)	187 (3.4)	1 (0.9)	39 (4.6)	1 (1.3)	52 (4.1)	<.001
Prior myocardial infarction	1199 (5.6)	639 (7.8)	174 (3.2)	286 (5.2)	8 (7.5)	33 (3.9)	4 (5.1)	55 (4.3)	<.001
Peripheral arterial disease	584 (2.7)	285 (3.5)	82 (1.5)	178 (3.2)	2 (1.9)	12 (1.4)	0	25 (2.0)	<.001
Smoking history	1406 (6.5)	603 (7.4)	246 (4.5)	418 (7.6)	14 (13.2)	42 (4.9)	2 (2.6)	81 (6.3)	<.001
Hypertension	12673 (58.9)	5173 (63.1)	2419 (44.2)	3838 (69.4)	62 (58.5)	471 (55.0)	35 (44.9)	675 (52.9)	<.001
Diabetes	7614 (35.4)	2600 (31.7)	1844 (33.7)	2355 (42.6)	46 (43.4)	308 (35.9)	33 (42.3)	428 (33.5)	<.001
Dyslipidemia	7423 (34.5)	3480 (42.4)	1286 (23.5)	1914 (34.6)	34 (32.1)	310 (36.2)	19 (24.4)	380 (29.8)	<.001
Heart failure	2500 (11.6)	1244 (15.2)	314 (5.7)	771 (13.9)	13 (12.3)	54 (6.3)	7 (9.0)	97 (7.6)	<.001
Atrial fibrillation / flutter	2089 (9.7)	1342 (16.4)	242 (4.4)	357 (6.5)	5 (4.7)	58 (6.8)	4 (5.1)	81 (6.3)	<.001
Chronic kidney disease	2784 (12.9)	1131 (13.8)	450 (8.2)	974 (17.6)	9 (8.5)	79 (9.2)	7 (9.0)	134 (10.5)	<.001
Hemodialysis	741 (3.4)	155 (1.9)	203 (3.7)	318 (5.7)	2 (1.9)	29 (3.4)	2 (2.6)	32 (2.5)	<.001
Cancer	2680 (12.4)	1340 (16.3)	477 (8.7)	647 (11.7)	12 (11.3)	80 (9.4)	6 (7.7)	118 (9.2)	<.001
Pulmonary disease	4015 (18.7)	1994 (24.3)	580 (10.6)	1076 (19.5)	23 (21.7)	126 (14.7)	14 (17.9)	202 (15.8)	<.001
Body mass index, mean (SD)	30.8 (8.5)	30.3 (8.5)	30.6 (7.5)	32.5 (9.3)	30.8 (8.5)	26.1 (5.6)	35.4 (10.2)	29.7 (7.3)	<.001
Missing	2,422	677	903	510	10	101	4	217	

Note: Missing values are noted where relevant. Race/ethnicity and sex are defined as determined by the registry during data collection. SD, standard deviation; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.

Table S2. Thromboembolic events and antithrombotic treatment of patients, overall and by race/ethnicity.

<i>Variable</i>	<i>All patients</i>	<i>Non-Hispanic White</i>	<i>Hispanic</i>	<i>Non-Hispanic Black</i>	<i>Native American</i>	<i>Asian</i>	<i>Pacific Islander</i>	<i>Other</i>
	n=21528 (%)	n=8202 (%)	n=5478 (%)	n=5531 (%)	n=106 (%)	n=857 (%)	n=78 (%)	n=1276 (%)
Venous thromboembolic events								
DVT (+/- PE)	508 (2.4)	176 (2.1)	110 (2.0)	171 (3.1)	2 (1.9)	15 (1.8)	1 (1.3)	33 (2.6)
PE (+/-DVT)	385 (1.8)	168 (2.0)	57 (1.0)	131 (2.4)	1 (0.9)	8 (0.9)	0	20 (1.6)
Arterial thromboembolic events								
Acute limb ischemia	44 (0.2)	12 (0.1)	6 (0.1)	23 (0.4)	0	2 (0.2)	0	1 (0.1)
Myocardial infarction	655 (3.0)	289 (3.5)	91 (1.7)	205 (3.7)	5 (4.7)	26 (3.0)	3 (3.8)	36 (2.8)
Ischemic stroke	168 (0.8)	61 (0.7)	28 (0.5)	57 (1.0)	0	11 (1.3)	0	11 (0.9)
Left ventricular thrombus	168 (0.8)	5 (0.1)	6 (0.1)	9 (0.2)	0	0	0	1 (0.1)
Bleeding requiring transfusion	747 (3.5)	246 (3.0)	148 (2.7)	255 (4.6)	7 (6.6)	28 (3.3)	3 (3.8)	40 (3.1)
Required ICU care	6604 (30.7)	2732 (33.3)	1430 (26.1)	1741 (31.5)	41 (38.7)	277 (32.3)	18 (23.1)	365 (28.6)
Missing	101							
Severe COVID-19*	4347 (20.3)	1553 (19.1)	1067 (19.6)	1217 (22.1)	26 (24.7)	199 (23.3)	7 (9.1)	278 (21.9)
Missing	104	32	39	18	1	2	1	11
Hospital Length of Stay								
Mean (SD)	10.0 (11.4)	9.9 (11.1)	9.9 (11.9)	10.3 (11.3)	11.5 (11.7)	9.7 (11.2)	9.6 (11.4)	10.0 (12.2)
Median (IQR)	6.5 (3.6-11.7)	6.6 (3.6-11.8)	5.9 (3.6-7.9)	6.6 (3.6-12.5)	7.6 (4.6-3.7)	6.4 (3.6-11.6)	5.6 (3.6- 9.9)	6.0 (3.5- 11.5)
Death	3326 (15.4)	1404 (17.1)	733 (13.4)	792 (14.3)	19 (17.9)	145 (16.9)	4 (5.1)	229 (17.9)
Prehospital antithrombotics								
Antiplatelet	5819 (27.1)	2754 (33.7)	913 (16.7)	1649 (29.9)	32 (30.2)	188 (22.0)	7 (9.0)	276 (21.8)
Missing	70	19	23	16	0	1	0	11
Aspirin	5327 (24.8)	2495 (30.5)	850 (15.6)	1523 (27.6)	30 (28.3)	172 (20.1)	7 (9.0)	250 (19.8)
P2y12 inhibitor	968 (4.5)	512 (6.3)	132 (2.4)	244 (4.4)	4 (3.8)	25 (2.9)	1 (1.3)	50 (4.0)

Other antiplatelet	150 (0.7)	65 (0.8)	14 (0.3)	60 (1.1)	2 (1.9)	4 (0.5)	0	5 (0.4)
Dual antiplatelet	621 (2.9)	314 (3.8)	83 (1.5)	177 (3.2)	4 (3.8)	13 (1.5)	1 (1.3)	29 (2.3)
Anticoagulant	2964 (14.1)	1503 (18.7)	548 (10.2)	720 (13.3)	9 (8.5)	62 (7.4)	5 (6.4)	117 (9.3)
Missing	442	163	102	135	0	18	0	24
Direct thrombin inhibitor	109 (0.5)	75 (0.9)	15 (0.3)	14 (0.3)	0	0	0	5 (0.4)
Factor Xa inhibitor	1429 (0.7)	825 (10.3)	160 (3.0)	340 (6.3)	3 (2.8)	31 (3.7)	3 (3.8)	67 (5.4)
Warfarin	519 (2.5)	315 (3.9)	59 (1.1)	119 (2.2)	2 (1.9)	5 (0.6)	1 (1.3)	18 (1.4)
Other anticoagulant	937 (4.4)	297 (3.7)	319 (5.9)	261 (4.8)	4 (3.1)	26 (3.1)	2 (2.6)	28 (2.2)
In hospital anticoagulants								
Prophylactic dose anticoagulant								
Subcutaneous heparin	3468 (25.0)	1328 (23.0)	629 (20.0)	1174 (32.2)	21 (25.9)	109 (23.6)	11 (19.3)	196 (28.5)
Missing	7681	2431	2332	1889	25	395	21	588
LMWH - low dose	6547 (47.4)	2612 (45.3)	1665 (53.1)	1553 (42.7)	45 (55.6)	290 (63.3)	34 (59.6)	348 (50.7)
Missing	7706	2440	2340	1891	25	399	21	590
Therapeutic dose anticoagulant								
Intravenous heparin	1381 (10.0)	576 (10.0)	218 (7.0)	444 (12.2)	7 (8.6)	37 (8.0)	4 (7.0)	95 (14.0)
Missing	7695	2422	2356	1881	25	393	21	597
LMWH - intermediate dose	1717 (12.4)	613 (10.6)	477 (15.2)	467 (12.8)	9 (11.1)	55 (11.8)	8 (14.0)	88 (12.8)
Missing	7679	2430	2338	1883	25	392	21	590
LMWH - full dose	1623 (11.7)	634 (11.0)	447 (14.2)	395 (10.8)	4 (4.9)	41 (8.8)	4 (7.0)	98 (14.3)
Missing	7673	2425	2336	1885	25	392	21	589
Argatroban	78 (0.6)	25 (0.4)	15 (0.5)	23 (0.6)	0	7 (1.5)	0	8 (1.2)
Missing	7493	2318	2330	1825	25	390	21	584
Bivalirudin	26 (0.2)	8 (0.1)	7 (0.2)	10 (0.3)	0	0	0	1 (0.1)
Missing	7493	2319	2328	1825	25	390	21	585
DOAC	1460 (10.4)	770 (5.8)	183 (5.8)	404 (10.9)	6 (7.4)	27 (5.8)	4 (7.0)	66 (9.6)
Missing	7500	2326	2329	1824	25	390	21	585

Apixaban	1108 (7.9)	561 (9.5)	145 (4.6)	317 (8.6)	6 (7.4)	22 (4.7)	3 (5.3)	54 (7.8)
Dabigatran	22 (0.1)	18 (0.3)	1 (<0.1)	2. (0.1)	0	0	0	1 (0.1)
Edoxaban	1 (<0.1)	0	0	0	0	0	0	1 (0.1)
Rivaroxaban	319 (2.3)	187 (3.2)	35 (1.1)	82 (2.2)	0	4 (0.9)	1 (1.8)	10 (1.4)
Warfarin	330 (2.4)	196 (3.3)	45 (1.4)	73 (2.0)	1 (1.2)	3 (0.6)	1 (1.8)	11 (1.6)
Missing	7510	2331	2331	1825	25	390	21	587

Note: Percentages are calculated out of the number of non-missing values for that variable. The number of missings for each variable is noted in the table where necessary. Race/ethnicity is defined as determined by the registry. Severe COVID-19 is defined as the need for invasive mechanical ventilation, extracorporeal circulatory or pulmonary support, or vasopressor or inotropes. DVT, deep vein thrombosis; PE, pulmonary embolism; ICU, intensive care unit; LMWH, low molecular weight heparin; DOAC, direct oral anticoagulant.

Figure S1. Creation of the analytic cohort and missing data.




Figure S2. Unadjusted Likelihood of Venous Thromboembolic Events by sex and race/ethnicity.




Figure S3. Sensitivity analysis of Venous Thromboembolic Events.




Figure S4. Unadjusted Likelihood of Arterial Thromboembolic Events by sex and race/ethnicity.




Figure S5. Sensitivity analysis of Arterial Thromboembolic Events.

